Enveda

AI’s greatest impact will not only be on the drugs we discover, but also on how quickly, affordably, and effectively we bring them to patients.

Transforming drug development will take more than technology or any single company. That is why we are excited to publish the full paper detailing the development and testing of our CMC Document Processor (CDP), created alongside @AnthropicAI.

When tested on a complete Phase 2 GMP batch record, CDP identified more major quality issues, provided more precise comments than human reviewers, and reduced review time by 89%.

The healthier world we want to build is bigger than one drug or one company. Let’s build the future together.

Read the paper: enveda.com/cmc-document-p…

Patients cannot wait another day for tomorrow’s medicines.

Today, bringing a drug to market can take more than 10 years and cost over $1 billion. A major contributor is the time and expense required to generate and review the documentation that helps to build medicines that are safe and effective.

That is why we are thrilled to partner with @AnthropicAI to transform drug development, starting with our clinical-stage programs. Together, we built tools to address two major early-stage bottlenecks: preparing a complete IND package and reviewing CMC batch records for release.

The results have been groundbreaking in speed, cost, and quality. Read more: anthropic.com/research/early…

Tech and startups are very much like sports: fast-paced, constant iteration, big bets and massive outcomes. So what happens when you get ESPN-like coverage of Tech?

You get @tbpn. @jordihays and @johncoogan are at the bleeding edge of what's happening in tech, startups and venture capital, bringing sharp perspectives and candid conversations with the people building what's next.

It's why we were so excited Enveda Founder & CEO @viswacolluru joined the show to speak about our recent $311M Series E and how we're bringing billions of years of evolutionary R&D to discover new medicines that serve the biggest indications people need and value.

Watch the full conversation.

#AI #Tech #Biotech

All of us have a stake in what the AI boom delivers. In @FastCompany, Enveda’s @viswacolluru and Bigyan Bista explore why better medicines could be among its largest payoffs.

fastcompany.com/91613320/the-a…

#AI #Biotech #LearningfromLife

We are excited to present at #EADV26 Late Breakers the mechanistic and biomarker data for our first-in-class oral treatment for atopic dermatitis and asthma, ENV-294.

ENV-294 targets a previously unengaged pathway, deepens our understanding of the fundamental biology underlying the disease, and presents hope for patients looking for new treatments.

Join us:

Late-Breaker Oral Presentation:
Title: A Previously Undrugged Target in Immune Therapeutics: Oral ENV-294 Provides First Clinical and Molecular Proof of Concept for RAC2 Modulation in Atopic Dermatitis (D3T01.4A)

Presenter: Ester Del Duca, M.D., Ph.D., Laboratory of Inflammatory Skin Diseases, Department of Dermatology, Icahn School of Medicine at Mount Sinai in New York City

Date/Time: Friday, October 2, 2026, 16:00-16:15 CEST / 10:00-10:15 EDT
Room: Hall A, Austria Center Vienna

Oral Presentation:
Title: ENV-294, a First-in-Class Oral Rac2 Modulator, Demonstrates Deep, Durable Efficacy with a Favorable Safety Profile in Moderate-to-Severe Atopic Dermatitis: Results from a Phase 1b Open-Label Study (FC01.1E)

Presenter: Leon Kircik, M.D., Clinical Professor of Dermatology, Icahn School of Medicine at Mount Sinai, New York; Adjunct Clinical Professor of Dermatology, Indiana University School of Medicine

Date/Time: Thursday, October 1, 2026, 09:10-09:20 CEST / 03:10-03:20 EDT
Room: Hall N, Austria Center Vienna

Read more: businesswire.com/news/home/2026…